Earnings Call · Q2 FY2023·2023-08-17

Q2 23EPS +55.88%·Rev n/aQ1 23EPS -47.83%·Rev n/aQ4 22EPS -52.94%·Rev n/aQ3 22EPS -90.00%·Rev n/a⚠ consensus missing

ZEVRA THERAPEUTICS, INC. ZVRA

Nichol Ochsner — Vice President, Investor Relations

Christal Mickle — Chief Executive Officer

LaDuane Clifton — Chief Financial Officer

+3.8%1d on move date+3.3% vs SPY3d−0.2%5d−4.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ZVRA calls or request research access.

More ZVRA calls Browse calls Request research access